Scientists are therefore encouraged to develop more specific biomarkers for detecting clinically significant PCa due to the low specificity of PSA testing for screening PCa and its limitations in identifying clinically significant PCa at an early stage and avoiding unnecessary biopsies (19). This evidence concerns the gene KLK3 and posterior cortical atrophy.